看病少花钱！医用耗材国家“团购”再出手

Core Insights - The national procurement of high-value medical consumables aims to reduce patient costs for treatments related to vascular stenosis and urinary stones, with the latest round of procurement yielding significant price reductions [1][2] Group 1: Procurement Details - The sixth batch of national organized procurement included 12 types of medical consumables, with 496 products from 227 companies bidding, and 440 products from 202 companies selected [1] - Drug-coated balloons, which help treat vascular stenosis, were included in this procurement, with all 42 products from 32 companies selected, ensuring high clinical compatibility [1] - The urological intervention category, previously a gap in procurement, saw 454 products from 195 companies bid, with 398 products from 170 companies selected, including specialized products for unique clinical needs [1] Group 2: Procurement Principles - The procurement process adhered to principles of stabilizing clinical use, ensuring quality, preventing excessive competition, and avoiding collusion [2] - Products were selected based on demand from medical institutions and their ability to supply nationwide, ensuring high clinical recognition and strong supply capabilities [2] - A new selection rule was implemented to prevent low pricing from distorting the market, using a benchmark of 65% of the average price for groups where the lowest bid was excessively low [2] Group 3: Impact on Healthcare Costs - The procurement strategy aims to link volume with price, effectively reducing inflated prices and addressing the issue of high medical costs for patients [2] - Since 2020, six rounds of national procurement have successfully acquired 142 types of medical consumables across various clinical fields, including cardiology, orthopedics, and urology [2] - The results of this procurement will be officially published soon, with patients expected to access high-quality and reasonably priced products by May 2026 [2]